Alert Number 227
Date: April 12, 2007
I have heard from a few members about the newly announced clinical trial using CAT-8015. This is often how we focus on new topics to write about, issues triggered by feedback or questions we get from you.
CAT-8015 is a new immunotoxin drug making its debut, similar to the drugs Ontak and LMB-2 that we discussed little over three years ago on our website. Immunotoxins are monoclonal antibodies (similar in that sense to Rituxan and Campath) but with the major difference that they carry with them a toxic payload to kill the cells they target. We bring you the clinical trial information and discuss the pros and cons of this approach in our latest article, CAT-8015 Clinical Trial.
On a different and sadder note, please join us in honoring the memory of our friend and board member Bill Duffy who passed away a few days ago. His obituary is posted on the Topics website.
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright © 2002-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.